Brief: Innate Pharma Updates On Monalizumab Combined With Cetuximab, Durvalumab

Innate Pharma SA

09/12/2021 10:03

Dec 9 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * INNATE PHARMA: MONALIZUMAB COMBINED WITH CETUXIMAB AND
DURVALUMAB DEMONSTRATES ANTI-TUMOR ACTIVITY IN FIRST-LINE
RECURRENT OR METASTATIC HEAD AND NECK CANCER AT ESMO
IMMUNO-ONCOLOGY 2021 CONGRESS
    * AFTER A MEDIAN FOLLOW-UP OF 16.3 MONTHS, PRELIMINARY DATA
SUGGEST ANTI-TUMOR ACTIVITY IN TRIPLET OF MONALIZUMAB, CETUXIMAB
AND DURVALUMAB IN FIRST-LINE TREATMENT OF R/M HNSCC
    * AS OF AUGUST 1, 2021, 40 PATIENTS WERE ENROLLED
    * SAFETY OF THIS CHEMOTHERAPY FREE REGIMEN WAS ACCEPTABLE
WITH A
LOW RATE OF DISCONTINUATION
    * THIRTEEN PATIENTS HAD A CONFIRMED RESPONSE WITH A 32.5%
OVERALL
RESPONSE RATE (95% CONFIDENCE INTERVAL (CI): 20-48), INCLUDING
THREE COMPLETE RESPONSES
    * SURVIVAL RATE AT 12 MONTHS WAS 58.6% (95% CI: 45-77) AND
MEDIAN
OVERALL SURVIVAL WAS 15 MONTHS (95% CI: 11.4 - NOT AVAILABLE)

Source text for Eikon:  ID:nBw5qvSbYa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))